Introduction
The scientific literature on psilocybin has expanded dramatically since the early 2000s, with landmark papers establishing its safety, therapeutic potential, and neurobiological mechanisms. This page highlights the most influential peer-reviewed publications — the studies that shaped the modern psychedelic renaissance and continue to guide clinical practice and policy.
Landmark Papers: Depression and Anxiety
Griffiths et al. (2006) — Psychopharmacology
Title: "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance"
Key finding: In a double-blind study of healthy volunteers, a single high dose of psilocybin produced mystical-type experiences that were rated among the most meaningful experiences of participants' lives. Two months later, 67% of participants rated it in their top five most spiritually significant experiences. This paper revived rigorous clinical research on psychedelics after a 30-year hiatus and established psilocybin's unique capacity to produce profound psychological experiences safely under controlled conditions.
Griffiths et al. (2016) — Journal of Psychopharmacology
Title: "Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer"
Key finding: A randomized, double-blind crossover trial at Johns Hopkins found that a single high-dose psilocybin session produced immediate, substantial, and sustained improvements in anxiety and depression in cancer patients. At 6 months, 80% of participants showed clinically significant antidepressant or anxiolytic responses. Published simultaneously with a parallel NYU study (Ross et al., 2016), both sets of results were remarkably consistent, lending strong replication support.
Davis et al. (2020) — JAMA Psychiatry
Title: "Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial"
Key finding: In adults with major depressive disorder (not cancer-related), two psilocybin sessions produced rapid and large antidepressant effects. At 4 weeks: 71% of participants showed a response (50%+ reduction in depression scores) and 58% were in remission. Effects were maintained at the 1-year follow-up reported in a 2022 companion paper. This was the first randomized controlled trial of psilocybin for MDD in a non-terminal population, published in one of psychiatry's most prestigious journals.
Carhart-Harris et al. (2021) — New England Journal of Medicine
Title: "Trial of Psilocybin versus Escitalopram for Depression"
Key finding: The first head-to-head comparison of psilocybin against a conventional SSRI antidepressant (escitalopram/Lexapro). While the primary outcome did not reach statistical significance, psilocybin showed numerically superior results on nearly all secondary measures including well-being, anhedonia, and work and social functioning. The study highlighted psilocybin's rapid onset compared to the 6-week ramp-up of SSRIs. Published in the NEJM, this paper brought psilocybin research to the broadest possible medical audience.
Landmark Papers: Addiction
Johnson et al. (2014) — Psychopharmacology
Title: "Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction"
Key finding: In an open-label pilot study at Johns Hopkins, 80% of participants who received psilocybin-assisted therapy were confirmed abstinent from smoking at 6-month follow-up — far exceeding the ~35% success rate of the best available pharmacotherapy (varenicline). At 12 months, 67% remained abstinent. The magnitude of mystical experience correlated with smoking cessation outcomes, suggesting that profound psychological experiences may drive therapeutic benefit.
Bogenschutz et al. (2015) — Journal of Psychopharmacology
Title: "Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study"
Key finding: An open-label pilot study at NYU showed significant reductions in alcohol use following psilocybin sessions. Drinking days and heavy drinking days decreased substantially in the weeks and months after sessions. The percentage of days abstinent increased from 11% at baseline to over 50% post-treatment. This proof-of-concept work supported a subsequent larger randomized trial (Bogenschutz et al., 2022, JAMA Psychiatry) that confirmed these findings.
Neuroimaging and Mechanisms
Carhart-Harris et al. (2012) — PNAS
Title: "Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin"
Key finding: The first fMRI study of psilocybin in humans. It found that psilocybin decreased activity in the default mode network (DMN) — a set of brain regions associated with self-referential thought, rumination, and the sense of ego. DMN suppression correlated with the intensity of subjective psychedelic effects. This paper launched an influential line of research into the neural basis of ego dissolution and its relationship to therapeutic outcomes.
Carhart-Harris et al. (2016) — The Lancet Psychiatry
Title: "Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study"
Key finding: The first study of psilocybin in treatment-resistant depression (patients who had failed at least two antidepressant courses). All 12 participants showed reductions in depression symptoms at 1 week; 8 of 12 met criteria for response at 3 months. Neuroimaging showed increased amygdala reactivity to emotional stimuli post-treatment — opposite to the blunting seen with SSRIs — suggesting a different mechanism of action consistent with facilitating emotional processing.
Carhart-Harris & Friston (2019) — Pharmacological Reviews
Title: "REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics"
Key finding: Introduced the REBUS (Relaxed Beliefs Under Psychedelics) model, proposing that psilocybin and other psychedelics work by flattening the brain's hierarchical predictive processing — reducing the weight given to top-down prior beliefs and allowing bottom-up sensory and emotional signals to have greater influence. This theoretical framework has become the leading mechanistic account of how psychedelics produce both acute effects and lasting therapeutic benefits.
Safety and Long-Term Effects
Griffiths et al. (2011) — Psychopharmacology
Title: "Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects"
Key finding: A dose-response study confirming that effects are dose-dependent and that high-dose sessions produce the most therapeutically relevant mystical experiences. Importantly, a 14-month follow-up found that participants who had high-dose experiences continued to rate them among the most meaningful and spiritually significant of their lives, with lasting positive changes in attitudes, mood, and behaviour reported by both participants and people who knew them.
Johnson et al. (2008) — Journal of Psychopharmacology
Title: "Human hallucinogen research: guidelines for safety"
Key finding: A foundational safety guidelines paper that standardised protocols for psilocybin research: screening criteria, dosing procedures, therapeutic support, set and setting requirements, and adverse event management. These guidelines have been adopted across research centres worldwide and underpin the favourable safety record of modern clinical psilocybin trials.
Where to Access These Papers
Most landmark psilocybin papers are available through open-access repositories or preprint servers:
- PubMed (pubmed.ncbi.nlm.nih.gov) — search by author and year; many papers have free PMC full-text versions
- Google Scholar (scholar.google.com) — often links to free PDF versions hosted by universities
- Semantic Scholar (semanticscholar.org) — AI-powered academic search with citation graphs
- Johns Hopkins Center for Psychedelic and Consciousness Research — publishes a reading list of key papers on their website
- MAPS (maps.org) — hosts a free literature library including historical and modern psychedelic research
- PsychedelicAlpha (psychedelicalpha.com) — curated news and links to current published research
How to Evaluate Research Quality
When reading psilocybin studies, consider these factors to assess evidence quality:
- Study design: Randomized controlled trials (RCTs) provide the strongest causal evidence; open-label pilots generate hypotheses but cannot rule out placebo effects
- Sample size: Many early studies had 10–30 participants; larger trials (n>100) provide more reliable estimates
- Blinding: True double-blinding is difficult with psychedelics — participants usually know if they received an active dose; this is an acknowledged limitation of the field
- Control conditions: Active placebos (e.g., low-dose psilocybin, niacin) are stronger controls than inert placebos
- Follow-up duration: Effects at 1 week may differ from effects at 6 months; look for long-term follow-up data
- Journal quality: Papers in JAMA Psychiatry, NEJM, The Lancet, PNAS, and Psychopharmacology undergo rigorous peer review
- Funding and conflicts of interest: Note whether studies are funded by companies with commercial interests in the outcome
Conclusion
The body of peer-reviewed research on psilocybin has grown from a handful of pilot studies in the early 2000s to hundreds of publications spanning clinical trials, neuroimaging, pharmacology, and long-term outcome research. The landmark papers described above established the scientific foundation for the current therapeutic renaissance. Reading primary sources — rather than relying on media summaries — is the best way to develop an accurate understanding of what the evidence actually shows, including its strengths and limitations.